Component: (Network and Table)
Network
00500 - Statement - Consolidated Statements of Cash Flows
(http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001466301 (http://www.sec.gov/CIK)
Consolidated Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Consolidated Statements of Cash Flows
 
 
 
Operating activities
 
 
 
Net loss
(349,137,000) 
(352,861,000) 
(160,031,000) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Share-based compensation expense
39,796,000  
40,357,000  
21,517,000  
Depreciation and amortization
1,141,000  
761,000  
444,000  
Amortization of premiums and discounts on available-for-sale securities
211,000  
1,400,000  
0  
Amortization of debt issuance costs
1,242,000  
1,205,000  
368,000  
Impairment of intangible asset
104,517,000  
89,557,000  
3,409,000  
Change in fair value of contingent purchase consideration
(24,661,000) 
(27,792,000) 
(3,301,000) 
Loss on disposal of equipment
105,000  
39,000  
67,000  
Deferred income taxes
(31,771,000) 
(28,874,000) 
761,000  
Changes in operating assets and liabilities
 
 
 
Accounts receivable
(121,000) 
0  
0  
Prepaid and accrued research and development expenses
(15,364,000) 
14,122,000  
18,112,000  
Other operating assets
1,039,000  
(4,380,000) 
(910,000) 
Accounts payable
(1,544,000) 
8,105,000  
(1,369,000) 
Other accrued expenses
7,867,000  
5,295,000  
3,882,000  
Net cash used in operating activities
(266,680,000) 
 
(253,066,000) 
 
(117,051,000) 
 
Investing activities
 
 
 
Purchases of property and equipment
(766,000) 
(3,035,000) 
(2,286,000) 
Proceeds from sale of property and equipment
65,000  
0  
0  
Purchases of available-for-sale securities
0  
(392,540,000) 
0  
Sales of available-for-sale securities
200,000,000  
140,997,000  
0  
Net cash provided by (used in) investing activities
199,299,000  
 
(254,578,000) 
 
(2,286,000) 
 
Financing activities
 
 
 
Proceeds from the sale of common stock, net of issuance costs
0  
298,509,000  
0  
Proceeds from the issuance of convertible senior notes, net of issuance costs
0  
0  
278,313,000  
Proceeds from the exercise of stock options and employee stock purchases
5,176,000  
5,971,000  
1,163,000  
Net cash provided by financing activities
5,176,000  
 
304,480,000  
 
279,476,000  
 
Effect of exchange rate changes on cash and cash equivalents
(365,000) 
(757,000) 
(690,000) 
(Decrease) increase in cash and cash equivalents
(62,570,000) 
 
(203,921,000) 
 
159,449,000  
 
Cash and cash equivalents at beginning of period
278,756,000  
482,677,000  
323,228,000  
Cash and cash equivalents at end of period
216,186,000  
 
278,756,000  
 
482,677,000  
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
7,188,000  
7,307,000  
0  
Non-cash investing and financing activities:
 
 
 
Acquired in-process research and development - milestone not paid as of period end
21,100,000  
0  
0